AbbVie Stock Chart Shows Pocket Pivot Cluster On FDA Breakthrough Therapy

Abbvie stock is a good long-term buy and hold on a “dream-team” pipeline of phase 3 trials.

Summary

  • AbbVie just received breakthrough therapy designation from the FDA for JAK1 inhibitor.
  • The company has a robust pipeline of drugs in phase 3 trials.
  • Over the last 5 years, revenue has been growing by 8.21% per year.
  • AbbVie stock has a bullish pocket pivot cluster with positive Twiggs Money Flow.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

    Mallinckrodt Stock Oversold Value Play On Sucampo Pharmaceuticals Buyout

    Mallinckrodt stock is a deeply oversold value play on a company that is working to turnaround its business.

    Summary

  • Mallinckrodt announced the acquisition of Sucampo Pharmaceuticals for $2.1 billion.
  • Mallinckrodt stock is deeply oversold after missing on revenue and a U.S. District Court recently invalidating 11 patents covering its second-largest product Inomax.
  • The company has maintained good revenue growth over the last 3 years.
  • TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

    The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.